University of South Carolina

Scholar Commons
Theses and Dissertations
2018

Family Planning Decisions After A Child’s Diagnosis Of Rett
Syndrome: A Pilot Study
Erin E. Huggins
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Genetic Phenomena Commons, and the Genetic Processes Commons

Recommended Citation
Huggins, E. E.(2018). Family Planning Decisions After A Child’s Diagnosis Of Rett Syndrome: A Pilot Study.
(Master's thesis). Retrieved from https://scholarcommons.sc.edu/etd/4723

This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and
Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
digres@mailbox.sc.edu.

FAMILY PLANNING DECISIONS AFTER A CHILD’S DIAGNOSIS OF RETT
SYNDROME: A PILOT STUDY
by
Erin E. Huggins
Bachelor of Science
Coastal Carolina University, 2016

Submitted in Partial Fulfillment of the Requirements
For the Degree of Master of Science in
Genetic Counseling
School of Medicine
University of South Carolina
2018
Accepted by:
Richard Ferrante, Director of Thesis
Lauren Baggett, Reader
Steven A. Skinner, Reader
Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Erin E. Huggins, 2018
All Rights Reserved.

ii

DEDICATION
To my beautiful grandparents-Grandma and Pop-for always believing in me, always
loving me, and always guiding me. Your presence has been felt every step of the way.

iii

ACKNOWLEDGEMENTS
This present study would not have been possible without the dedication of the entire Rett
syndrome community. Special thanks to Paige and Janice of RettSyndrome.org for their
commitment to this project, to Greenwood Genetic Center for their award-winning care
of those with Rett syndrome, and finally, to the dedicated parents of children with Rett
syndrome. Their strength and tireless advocacy was a constant inspiration for the
completion of this project.

iv

ABSTRACT
Rett syndrome (RTT) is a rare neurodevelopmental disorder that primarily affects
females. In 99% of cases, RTT is believed to occur sporadically, or de novo. However, in
rare cases, RTT can be passed down from parent to child through gonadal mosaicism or
asymptomatic carrier mothers. It is known that having a child with an inherited genetic
condition can lead to changes in family planning; however, little research has
investigated this phenomenon in sporadic genetic conditions, such as RTT. This present
study used a questionnaire to assess family planning decisions of parents of children with
RTT. Forty-three percent of respondents reported that their family planning changed. The
primary reason for reproductive stoppage was due to caregiver strain, and of those that
chose reproductive continuation, the primary change was in the age gaps between their
children. Parents were also asked to explain what they were told by healthcare providers
about the recurrence of RTT and if they received genetic counseling. Seventy-eight
percent reported they were told there was a 1% or less chance of recurrence of RTT and
34% received genetic counseling. There was no significant association between those
who received genetic counseling and those who altered their family planning decisions.
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CHAPTER 1
BACKGROUND
A Brief History of Rett Syndrome
Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder that occurs
in about 1 in 10,000 females and very rarely affects males (Laurvick et al., 2006).
Individuals with RTT develop normally for a period between 6-18 months, followed by a
period of regression. Affected individuals lose purposeful speech, hand use, and
ambulation; they may also develop microcephaly and/or seizures. RTT was originally
described by Dr. Andreas Rett, an Austrian neurodevelopmental pediatrician, in the
1960s (Rett, 1966). Rett’s papers, written in German, were not well-known among
European physicians at the time. Swedish pediatric neurologist Dr. Bengt Hagberg noted
girls with similar features around the same time yet was unaware of the findings of
Andreas Rett. It was not until 1983 that Rett syndrome was featured in an English
publication by Hagberg and colleagues in Annals of Neurology (Hagberg et al., 1983).
This paper described 35 female patients across France, Portugal, and Sweden all with
similar features, including developmental regression, severe dementia with acquired
microcephaly, loss of purposeful hand movements, autistic behaviors, and truncal and
gait ataxia. Hagberg et al. (1983) concluded that these features were so striking that there
was likely an underlying etiology that had not been previously described. Laboratory
tests were inconclusive, and an exclusively female patient population raised suspicion of
an X-linked dominant form of inheritance with lethality in males, but with little evidence
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to support this claim. In addition, only one familial case out of the patients described in
this paper was reported; two half-sisters born to the same unaffected mother with an
unaffected half-brother from a third father (Hagberg et al., 1983). Thus, the inheritance
pattern of Rett syndrome became a challenge to pinpoint.
Genetics
In 1999, Amir et al. were the first to report that mutations in the MECP2 (methyl-CpGbinding protein 2, OMIM # 300005) gene, located at Xq28, caused RTT. Mutations were
identified in the coding regions of MECP2 in 5 of 21 sporadic cases, as well as one
familial case-a set of half-sisters that share the same mother (Amir et al., 1999).
A larger study in 2008 investigated genotype-phenotype correlations in a crosssectional study of 245 females with RTT. Of note, 97% of affected girls and women in
this study had a MECP2 mutation (Neul et al., 2008). By this time, over 200 mutations
had been identified; however, 8 mutations accounted for 60% of cases according to data
from RettBASE (Christodoulou et al., 2003). While genotype-phenotype correlations
have yet to be fully described, Neul et al. (2008) determined that specific mutations
impact clinical severity. Importantly, it was observed that certain mutations are
associated with increased phenotypic severity in specific categories: ambulation, hand
use, and language (Neul et al., 2008).
Natural History
Individuals with RTT develop typically between the ages of 6-18 months, followed by a
period of regression (Amir et al., 1999). RTT is divided into typical (classic) and atypical
(variant) forms. In 2010, a revision of the 2002 diagnostic criteria (Hagberg et al., 2002)
was published to streamline clinical diagnosis, add required criteria, and distinguish
variant forms of RTT. These criteria are continually being evaluated and will be updated
2

appropriately as more data becomes available to clinicians and researchers. Currently, the
main criteria for RTT are: partial or complete loss of acquired purposeful hand skills,
partial or complete loss of acquired spoken language, gait abnormalities, and stereotypic
hand movements. All main criteria are required for a diagnosis of typical RTT, and two
of these are required for a diagnosis of atypical RTT. In addition, supportive criteria
include breathing disturbances when awake, bruxism when awake, impaired sleep
pattern, abnormal muscle tone, peripheral vasomotor disturbances, scoliosis/kyphosis,
growth retardation, small cold hands and feet, inappropriate laughter/screaming spells,
diminished response to pain, and intense eye communication (Neul et al., 2010).
Due to the wide phenotypic spectrum, variant forms of Rett syndrome have been
described and named for their phenotype; for example, the “preserved speech variant,”
also known as the Zapella variant, is considered the mildest RTT phenotype and is the
most common atypical variant. A 2009 study identified 28 out of 29 females with Zapella
variant RTT as having a missense or late-truncating MECP2 mutation. Even still, the
patients with this variant exhibited variable phenotypes (Reniere et al., 2009). A second
variant called the “early seizure variant,” or the Hanefield variant, is characterized by
early-onset seizures (typically before developmental regression). MECP2 mutations are
less common in this variant, and mutations in the CDKL5 gene (also located on the X
chromosome) are more likely (Archer et al., 2006). The third variant is called the
“congenital variant,” or the Rolando variant, and affected individuals present with
abnormal development from birth. It has been shown that mutations in the FOXG1 gene
(located on chromosome 14) may be more likely to cause the congenital form of RTT
(Ariani et al., 2008). However, CDKL5 and FOXG1-associated conditions are now
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recognized as distinct diagnoses from RTT and are no longer included in current studies
of RTT.
MECP2 mutations are also known to be responsible for a phenotypic spectrum
outside of what is typically expected in RTT. In 1999, Wan et al. described a familial
case in which a woman was found to have a mild learning disability and some motor
problems. This woman had a sister and daughter both with classic RTT, as well as a son
who was hemizygous for the mutation and passed away at one year of age due to neonatal
encephalopathy (Wan et al., 1999).
While phenotypically variable, RTT typically presents in a severe form and leads
to lifelong disability. The quality of life of individuals with RTT has dramatically
changed in recent years due to advanced therapies and interventions. Survival for classic
and atypical RTT is greater than 70% at 45 years, and survival into the 5 th decade has
become typical (Tarquinio et al., 2015). According to Tarquinio et al. (2015), “presumed
cardiorespiratory complications” are the leading cause of death in females with classic
RTT according to data from the US RTT Natural History Study. With strong physician
monitoring of nutrition, gastrointestinal issues, scoliosis, aspiration risk, and epilepsy, the
lifespan of individuals with RTT may continue to increase as these risk factors are
managed.
Inheritance
RTT is considered de novo, or “random,” in approximately 99% of cases. Few familial
cases have been reported and are likely due to gonadal mosaicism in either the paternal or
maternal germline, or to highly skewed X- chromosome inactivation (XCI) patterns in
carrier mothers (Zhang et al., 2012). Zhang et al. (2012) found mutation type varied
between paternally and maternally derived mutations in a cohort of Chinese patients. It
4

was found that point mutations are more likely to be of paternal origin, while single
nucleotide gains/losses are more likely to be of maternal origin. Additionally, it was
found that most familial cases were due to maternally derived mutations, due to either
gonadal mosaicism or carrier mothers with highly skewed X-inactivation. These
mechanisms are discussed in the succeeding paragraphs.
Gonadal mosaicism refers to the presence of more than one distinct cell line in the
germ cells (egg or sperm). Gonadal mosaicism may occur in one of two ways. In some
cases, a mutation occurs in a germ cell which then continues to divide and creates a
unique cell line. In other cases, a mutation can occur in a very early somatic cell, which
then separates into somatic and germ cells, leading to both somatic and gonadal
mosaicism. Mosaic individuals may exhibit mild symptoms of the condition or be
completely asymptomatic (Zlotogora, 1998).
X-inactivation refers to the silencing of either the maternal or paternal Xchromosome in female cells. The selection of the silenced chromosome is often random
and varies from cell to cell; one cell population expresses the maternal X chromosome,
while the remainder of the cells express the paternal X chromosome. This is referred to as
the “X-inactivation pattern” and can vary from female to female; some may express a
50:50 ratio, while others may express a more highly skewed ratio, such as 90:10 or 80:20
(Plenge et al., 2002). It has been proposed that unaffected mothers of children with an Xlinked intellectual disability (XLID) syndrome, such as Rett syndrome, may have a
highly skewed X-inactivation pattern. Plenge et al. (2002) suggest that skewed XCI
patterns are more common in mothers of children with XLID syndromes due to selection
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against the X-chromosome containing the mutation, leading to higher XCI patterns
(≥80:20).
Zhang et al. (2012) suggests that there are important clinical implications for
mutation interpretation. For example, when insertion/deletion is observed in a patient,
this is more likely due to a maternally derived mutation. In this case, the mother has a
higher chance of being a carrier of the mutation or having germline mosaicism, and the
family may be counseled on a modified recurrence estimate from the typical 1%. In the
case of an affected child born to apparently healthy parents, the chance of recurrence can
be as high as 50% if one parent is mosaic (Wilbe et al., 2017). However, there are
currently no accepted methods in practice for analysis of sperm or eggs for germline
mosaicism.
Approximately 99% of cases of females with RTT are de novo and have been
identified as almost exclusively arising from mutations on the paternal X chromosome
(Trappe et al., 2001; Zhang et al., 2012). This is a likely explanation for the high female:
male ratio of individuals with RTT. It was previously thought that RTT was male lethal;
however, males with MECP2-related conditions have been reported and may have
inherited the mutation either through a maternal de novo mutation or through carrier
mothers (Trappe et al., 2001). Additionally, after determining that de novo MECP2
mutations were primarily paternally derived, Trappe et al. (2001) concluded that these
mutations were not in fact male lethal, and the paucity of affected males could be
attributed to the fact that boys do not receive an X chromosome from their fathers.
Venȃncio et al. (2007) describe a case report of a young female with classic RTT found
to have a mutation in MECP2. The same mutation was found in her younger brother who
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presented with severe growth and developmental delays early in life. He was found to
have severe neurological abnormalities and died at 21 months of age due to
complications from infection. However, the mutation was not present in blood from
either parent, thus suggesting a case of maternal germline mosaicism (Venȃcio et al.,
2007). Typically affected males present with a severe phenotype, as all cells will express
the mutated copy of MECP2. Four boys with progressive encephalopathy were described
by Kankirawatana et al. (2006) All four patients had de novo mutations in MECP2.
Symptoms included failure to thrive, respiratory insufficiency, microcephaly, and
abnormal movements (Kankirawatana et al., 2006). This suggests that MECP2 analysis
should be considered in males with these presenting features and speaks to the wide
phenotypic spectrum of Rett syndrome, especially in males.
Family Planning in The Presence of Genetic Conditions
In this present study, family planning refers to decisions related to reproduction.
Reproductive stoppage, or the decision to discontinue having children after a diagnosis is
made, is a known phenomenon among families with a child diagnosed with autism
(Wood et al., 2014; Hoffmann et al., 2014). Autism, like RTT, is not often diagnosed
until the affected child is a few years old. Reproductive decisions may change after this
diagnosis is made; Hoffmann et al. (2014) found that the first few years after a child’s
diagnosis of autism, parents had subsequent children at a rate similar to controls.
However, birth rates changed in the following years, and it was found that families had
another child at a lower rate than controls (Hoffmann et al., 2014). This idea has yet to be
studied in the RTT community. We hypothesize that families of children with RTT may
make similar decisions, given that the diagnosis of RTT is often not made until early
childhood after the child regresses. In addition, it is imperative to better understand the
7

factors that may contribute to these reproductive decisions, such as caregiver strain,
interpretation of recurrence risk, and psychosocial aspects such as fear, guilt, and shame.
Upon receiving a diagnosis of Rett syndrome, caregivers and family members
must learn to manage not only their child’s health, but their own health as well. It is well
understood that in general, parents of children with disabilities experience more adverse
mental and physical health outcomes (Yamaoka et al., 2015). Laurvick et al. (2006)
investigated this claim specifically in mothers of children with RTT. It was found that
maternal physical and mental health is lower than the general population. Child behavior,
caregiver demands, and family function were identified as the major predictors of
maternal physical and mental health outcomes (Laurvick et al., 2006). Mothers of
children with RTT are also at risk for adverse mental health outcomes such as severe
depression (Sarajlija, Djuri, & Tepavcevi, 2013), and are also reported to have poorer
mental health than physical health (Killian Jr. et al., 2016).
Other non-genetic factors may play a role in a family’s decision to have more
children after an RTT diagnosis. Because women with Rett syndrome now may live into
middle age and beyond (Kirby et al., 2010), caregivers are responsible for ensuring their
child receives lifelong care. This may be through dedicating themselves to the care of
their child, but the question remains who will care for the child should he or she outlive
the parents. Some parents may assume the siblings of their affected child will take charge
of the care. There is currently no available research analyzing associations between
caring for a child with RTT and the decision to have more children after the diagnosis is
made. The strain on parents who are also caregivers coupled with the uncertainty of who
will care for the child should they become unable and the uncertainty of having another
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child with RTT are among many factors that may influence reproductive decisions.
Being aware of these factors may provide the healthcare professionals caring for these
families with increased knowledge of the impact a RTT diagnosis has on a family. By
having a working knowledge of the possible questions and uncertainties parents of
children with RTT face, healthcare professionals may be able to address them more
accurately to provide more personal care for these families.
The quality of life measures for caretakers of individuals with RTT are similar to
those who are caring for individuals with other neurodevelopmental disorders.
Difficulties with common features of RTT such as poor feeding and ambulation may
have an impact on the physical and mental health of the caregiver (Killian Jr. et al.,
2016). RTT leads to a lifetime of disability, and caregiver demands can be great.
Caregiver strain due to poor mental and physical health may certainly play a role in
family planning; however, parents of children with RTT may not experience the same
level of stress in caring for their children in early childhood as they may later in
childhood and adulthood. It is not clearly understood if parents are making decisions
based on their perceived future caregiving responsibilities, versus their current
responsibilities when their child receives a diagnosis.
In many cases, the specialist making a RTT diagnosis is a neurologist,
developmental pediatrician, or a geneticist (Tarquinio et al., 2015). It is currently unclear
to what extent these families are receiving genetic counseling, if at all. It is also not clear
whether families are receiving the most accurate and up-to-date information on the
genetics of RTT. It is not yet known if recurrence risk, typically quoted at 1% except in
cases of gonadal mosaicism or carrier mothers, is a major factor in these parents’
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decision-making processes when it comes to future pregnancies. This present study aims
to assess if families are receiving genetic counseling and by whom, as well as to
determine what information they were given at the time of diagnoses that may have had
an impact on family planning decisions.
Parents of children diagnosed with RTT face a unique challenge when it comes to
chance of recurrence. While the majority of cases are de novo, mothers may be
unrecognized carriers of a MECP2 mutation due to skewed X-inactivation, and both
maternal and paternal gonadal mosaicism are virtually impossible to rule out. This
uncertainty may add a layer of complexity to families faced with making decisions about
future pregnancies. The following quote is from the parent of a child with RTT regarding
the diagnostic odyssey her family faced. (Knott, Leonard, & Downs, 2011):
“Not long after diagnosis, I had a test to confirm that I was not a silent carrier of
the mutation and when given the all clear, my husband and I decided to have
another child. We had read that the chances of having a second child with RTT
was miniscule, however, the concern was always present. (p.11)”
The author went on to have a healthy daughter without RTT after her first daughter was
diagnosed with RTT, yet she does not specify that she received any kind of family or
genetic counseling on the matter to reach that decision. Parents of newly diagnosed
children have many questions, one of them being “How will this affect planning for
future children?” (Downs & Leonard, 2016). Currently, there is little literature on family
planning decisions after a diagnosis of a typically de novo condition is made.
There is, however, an abundance of literature regarding family planning decisions
following a diagnosis of a condition in which the inheritance pattern is well-established.
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Fragile X syndrome (OMIM #300624) is the most common cause of autism and
intellectual disability in males (Hunter et al., 2014). Interviews of mothers with a known
mutation in the gene FMR1, which incurs a 50% chance of passing on Fragile X
syndrome to their children, revealed that 77% of women decided against having more
children after learning their carrier status (Raspberry & Skinner, 2011). These women
reported several factors that influenced their decision making, including reproductive
risk, emotional/financial strain of another child with a disability, and the implication of
“social judgments” should they choose to have more children knowing the risks involved.
Another survey of individuals with a diagnosis of Peutz-Jeghers syndrome, an
autosomal dominant cancer predisposition syndrome, revealed that 29% of respondents
reported that their diagnosis influenced their family planning decisions, and 19% of these
reported that they do not wish to have children at all (van Lier et al., 2012). These
questions have yet to be explored in the RTT community. Although it is now known that
RTT is not typically inherited from a parent as in Peutz-Jeghers syndrome, it was initially
thought to be inherited from the mother prior to the discovery that MECP2 mutations
were responsible. It is possible that healthcare professionals outside the field of genetics
may not have the most up-to-date or accurate information on the recurrence risk of RTT.
In this study, we aim to assess to what extent a RTT diagnosis affects family
planning decisions. We aim to identify factors such as parental interpretation of
recurrence risk, the accuracy of recurrence information provided at the time of diagnosis,
and the extent to which genetic counseling was received by families. In addition, we will
investigate the rates at which parents elected prenatal diagnosis of RTT as well as the
uptake of parental genetic studies to determine carrier status for RTT.
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CHAPTER 2
FAMILY PLANNING DECISIONS AFTER A CHILD’S DIAGNOSIS OF
RETT SYNDROME: A PILOT STUDY1

1

Huggins, E.E., Baggett, L., Skinner, S.A., Ferrante, R. (2018) Family Planning
Decisions After a Child’s Diagnosis of Rett Syndrome: A Pilot Study. (to be
submitted)
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INTRODUCTION
Rett syndrome (RTT) is a rare neurodevelopmental genetic condition that affects about
1/10,000 girls and very rarely affects males (Laurvick et al., 2006). It is an X-linked
dominant condition caused by mutations in the MECP2 (methyl-CpG-binding protein 2,
OMIM # 300005) gene, located at region Xq28 (Amir et al., 1999). RTT is characterized
by a period of normal development between 6-18 months of age, followed by a period of
regression. Though the clinical phenotype varies, the main diagnostic criteria for a
diagnosis of RTT include partial or complete loss of acquired purposeful hand skills,
partial or complete loss of acquired spoken language, gait abnormalities, and stereotypic
hand movements (Neul et al., 2010). Other symptoms include seizures, vasomotor
disturbances, scoliosis/kyphosis, and abnormal muscle tone.
RTT is considered sporadic in approximately 99% of cases. In the past, it was
thought RTT was male lethal due to the paucity of affected males in the patient
population. However, it was found that de novo cases typically arise due to mutations on
the paternally inherited X chromosome (Trappe et al., 2001; Zhang et al., 2012). Few
familial cases have been reported and are most likely maternally inherited. These cases
are likely due to either parental gonadal mosaicism or carrier mothers with highly skewed
X-inactivation (Zhang et al., 2012). While testing X-inactivation patterns in mothers is
possible, it is nearly impossible to accurately screen either parent for gonadal mosaicism,
making the assessment of recurrence risk a challenge.
In the event of an apparently sporadic case, parents of a child diagnosed with RTT
are often told that recurrence is unlikely (i.e., < 1%), however; parental perception of this
risk estimate has not been well-studied. Additionally, it is not clear to what extent parents
13

are receiving genetic counseling, and if they are informed of the possibility of an
increased recurrence risk due to undetected gonadal mosaicism or carrier mothers. These
uncertain risk assessments may alter family planning decisions after a child’s diagnosis.
In this present study, family planning refers to decisions related to reproduction.
Reproductive stoppage, or the decision to discontinue having children after a diagnosis is
made, is a known phenomenon among families with a child diagnosed with autism
(Wood et al., 2014; Hoffmann et al., 2014). As in RTT, autism is often undiagnosed until
the affected child is a few years old and symptomatic. The inheritance of autism is
variable and multifactorial, and many parents never receive an explanation of the cause of
autism in their child. Due to the limits of genetic testing, recurrence risk for autism is
often difficult to explain and interpret for families. Parents of children with autism may
experience a similar type of uncertainty as parents of children with RTT. One study
reported that, in the first few years after a child’s diagnosis of autism, parents had
subsequent children at a rate similar to controls. However, birth rates changed in the
following years, and it was found that families had another child at a lower rate than
controls (Hoffmann et al., 2014). This idea has yet to be studied in the RTT community.
We hypothesize that families of children with RTT may make similar decisions, given
that the diagnosis of RTT is often not made until early childhood after the child regresses
and there is a similar level of uncertainty involved.
Reproductive decision-making in the wake of a genetic syndrome with an
established inheritance pattern has been well-studied. While RTT is the leading cause of
intellectual disability in females, Fragile X syndrome is the leading cause of autism and
intellectual disability in males. Fragile X syndrome is caused by a trinucleotide repeat
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expansion in the FMR1 gene, also located on the X chromosome. Typically, mothers are
carriers of an expansion, and have a 50% chance to pass on the full expansion to their
sons in an X-linked recessive pattern. A study of known Fragile X carriers revealed that
77% of women decided against having more children after learning their carrier status
(Raspberry & Skinner, 2011). While the inheritance pattern of Fragile X syndrome and
RTT differ, there is phenotypic overlap between the two syndromes. Women in this study
reported several factors that influenced their reproductive decision making, including
reproductive risk, emotional/financial strain of another child with a disability, and the
implication of “social judgments” should they choose to have more children knowing the
risks involved. This present study aims to identify factors in this same decision- making
process for both mothers and fathers of children with RTT.
RTT is a condition characterized by severe lifelong disability. As described by
mothers in the above-mentioned study, there is both emotional and financial strain in
caring for one child with a disability, let alone multiple children with disabilities. The
mental and physical health of parent caregivers of children with special needs have been
well-studied. In general, parents of children with disabilities experience increased adverse
mental and physical health outcomes (Yamaoka et al., 2015). Specifically, mothers of
children with RTT are known to have poorer mental and physical health than the general
population (Laurvick et al., 2006) and are at an increased risk for depression (Sarajlija,
Djuri, & Tepavcevi, 2013). Caregiver strain, along with uncertainty surrounding
recurrence risk, must be considered when assessing a family’s desire to alter their family
planning strategy. It is hypothesized that a combination of genetic and non-genetic
factors ultimately influences parental family planning decisions and strategies. Families
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must navigate complex genetic information, manage the ongoing medical needs of their
child with RTT, and deal with parenthood and the emotional distress that comes
regardless of a genetic diagnosis. In addition, parents may experience feelings of guilt,
shame, and fear, and may have little guidance in managing this distress. This present
study aims to assess to what extent a RTT diagnosis affects family planning decisions,
the accuracy of information given to parents at the time of diagnosis, and the measures
parents have taken to manage these risks such as prenatal diagnosis of RTT and parental
genetic studies.

MATERIALS AND METHODS
Participants
Approval for this study was obtained from the University of South Carolina Institutional
Review Board. Biological parents of individuals of any age with a clinical and/or genetic
diagnosis of RTT were eligible to participate in this study. Parents of children with
known MECP2 duplications, FOXG1 alterations, or CDKL5 variants were excluded from
this study. Less information is widely available on these conditions, and although they
are associated with RTT, they do not carry the same implications as a diagnosis of Rett
syndrome presumed or known to be to be associated with a MECP2 alteration. An
invitation was sent to members of RettNet, a community for the family members of
individuals with RTT, through an email listserv. The invitation was sent once a month for
three months (October 2017-January 2018). In addition, an invitation to participate was
posted on the public Facebook page RettSyndrome.org once a month for three months.
There were 323 individuals that completed at least part of the online survey. Of these,
304 completed at least 80% of the survey and met the inclusion criteria.
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Questionnaire Design
We developed an online questionnaire using SurveyMonkey. The questionnaire had four
major sections. The first section included information on the diagnosis of the individual
with RTT (age, age at diagnosis, diagnosis delivery, genetic status). The second section
included questions related to subsequent pregnancies after their child was diagnosed with
RTT (number of pregnancies, type of genetic screening/testing during pregnancy, genetic
diagnosis for RTT). Participants were prompted to answer the same set of questions for
up to 4 subsequent pregnancies. The first two sections consisted of primarily multiplechoice questions with few free-response questions. The third section included several indepth free response questions (how their child’s diagnosis impacted their family
planning, what information they received about recurrence risk). The final section
included participant demographics. The questionnaire was pilot tested by a staff member
of RettSyndrome.org, who is also the mother of a daughter with RTT. The questionnaire
took approximately ten minutes to complete.
Analysis
Descriptive statistics were used to describe quantitative questionnaire data. Chi-square
analysis was used to analyze relationships between genetic counseling and family
planning. Thematic analysis performed by the principal investigator was used to analyze
free-response question data.
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RESULTS
2.1 Demographics. A total of 323 participants completed all or part of the survey. Only
biological mothers and fathers of children with RTT were eligible to participate in this
study. Those that reported they were not biological parents and those that did not
complete greater than 80% of the survey were excluded from analysis, resulting in a total
of 304 responses. Participants could skip any question they did not want to answer; thus,
there are variations in the number of responses per question analyzed. Of the participants
that met inclusion criteria, 89.5% (272/304) were mothers and 10.5% (32/304) were
fathers. Participants were primarily Caucasian, college-educated, and married.
Demographics are outlined in Table 2.1.
2.2. Family Planning Decisions. Forty-three percent of participants (117/272) responded
that having a child with RTT changed their family planning decisions, 50.4% (137/272)
responded that it did not, and 6.6% (18/272) were unsure (Figure 2.1). Several major
themes emerged when analyzing how a diagnosis of RTT impacted family planning.
Detailed responses were provided by 194 participants regarding how their family
planning decisions were or were not altered. Three major themes emerged: parental
decisions to stop reproduction, parental decisions to continue reproduction, and parental
decisions to make no changes to their reproductive plans based on their child’s RTT
diagnosis. Subthemes are presented in Figures 2.2-2.4. Analysis of these themes and their
subthemes, as well as examples of participant responses, are outlined in Table 2.2.
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2.2a. Decision to stop reproduction. There were 70 responses indicating that parents
decided to stop having children after their child’s diagnosis of RTT. Subthemes in this
category include stoppage due to caregiver strain (38/70), the decision to dedicate their
care to the affected child/did not wish to have more children (14/70), and fear/uncertainty
of having another child with RTT or other special needs (18/70).
2.2b. Decision to continue reproduction. There were 37 responses indicating that parents
decided to continue having children after their child’s diagnosis of RTT. Subthemes in
this category include continuation for the reason of having a sibling either for their child
with RTT or for a typical child (12/37), continuation because the interpretation of the risk
for future affected children was low (8/37), and a decision to have more children but with
different age gaps between children than previously planned (17/37).
2.2c. No change in family planning decisions. There were 82 responses indicating that a
diagnosis of RTT did not alter family planning decisions. One group of participants
indicated that they were already done having children by the time their child was
diagnosed (34/82). Ten participants were already pregnant at the time of the diagnosis, 16
participants responded that they were still planning to have the same number of children
regardless of the diagnosis, 7 participants reported having either a tubal ligation or
vasectomy prior to becoming aware of their child’s diagnosis, and 5 participants were
mothers who responded that their age was the major factor in stoppage. A group of 11
participants had miscellaneous reasons to stop reproduction that did not fit into categories
including inability to get pregnant or did not give specific reasons.
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2.2d. Undecided. A group of five participants reported that they were still unsure if their
family planning decisions would change. Reasons include parental disagreement (2/5)
and difficulty coming to a decision due to a variety of factors (3/5).
2.3 Future Pregnancies. Participants were asked questions regarding subsequent
pregnancies after their child was diagnosed; 46.7% (136/291) reported that they had at
least one subsequent pregnancy and 53.3% (155/291) reported that they had no
subsequent pregnancies. Prenatal diagnostic testing via amniocentesis or chorionic villus
sampling (CVS) for RTT was performed on 27 pregnancies, and prenatal diagnostic
testing for other conditions such as chromosome abnormalities was performed for 37
pregnancies. Of note, none of the reported pregnancies tested for RTT prenatally were
affected.
2.4. Recurrence Risk Information. Participants were asked questions regarding
reproductive information they received prior to having future children; 55.5% (146/263)
report that they were told their chances of having future children with RTT, 39.2%
(103/263) reported they were not told their chances, and 5.3% (14/263) were unsure. Of
the 263 that answered this question, 183 gave detailed responses regarding the
information they received. Thematic analysis revealed five different categories of
information participants received (Figure 2.5). Many respondents (78.7%, 144/183)
reported that they were told their chances of having another affected child were 1% or
less, or unlikely. Of note, 11 of these responses specifically mentioned being counseled
on gonadal mosaicism (both maternal and paternal) and the possibility of carrier mothers.
The second most common response (11.4%, 21/183) was by parents that were not told
anything or did not have this discussion with their providers. A small subset (3.3%,
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6/183) reported that this information was not known at the time of their child’s diagnosis,
and another small subset (3.3%, 6/183) were told a higher number, such as 5%, 25%, or
50% or more. Of note, one of these responses indicated that the mother was found to be
an asymptomatic carrier for RTT; therefore, she was correctly informed her chance of
having an affected child is 50%. Further, 3.3% (6/183) were told the chance was zero or
impossible.
2.4a. Parental Genetic Testing. Participants were asked if either parent had received
genetic testing to determine their carrier status for MECP2 mutations. There were 272
responses to this question; 16.5% (45/272) report the mother only had genetic testing,
1.5% (4/272) report the father only had genetic testing, 22.8% (62/272) report both
parents had testing, 58.5% (159/272) report neither had testing, and 0.7% (2/272) were
unsure. Of the mothers that received testing, two were found to be asymptomatic carriers.
There were no reports of carrier fathers.
2.5. Genetic Counseling. Participants were asked whether they had received genetic
counseling. There were 272 responses to this question; 34.6% (94/272) reported they had
received genetic counseling. Of those that chose to disclose who provided the genetic
counseling, 82% (82/100) reported they were counseled by a genetic counselor, and 18%
(18/100) were counseled by another physician or provider. Sixty-one percent of
respondents (166/272) reported they did not receive genetic counseling, and 4.4%
(12/272) were unsure. There was no significant association between families receiving
genetic counseling and altering their family planning decisions (p= 0.8).
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DISCUSSION
The themes identified in this present study allude to previous findings in the literature
regarding family planning. As expected, there were more participants that made decisions
to stop reproduction based on non-genetic factors (i.e., caregiver strain), versus stopping
based on the recurrence risk of RTT. While only about half of participants reported being
informed of their chances to have another affected child, participants more frequently
reported that they stopped reproduction based on recurrence risk than continued despite
recurrence risk. Families are often quoted a “1% or less” recurrence risk (except in
situations of gonadal mosaicism or carrier mothers) when discussing the chances for their
future children to have RTT. This study was the first to investigate how parents of
children with RTT interpreted this chance and applied it to their family planning
decisions.
Caregiver strain was the most commonly reported reason for reproductive
stoppage. It is known that individuals with RTT have many complex medical issues,
including seizures, feeding problems, mobility issues, and poor communication skills.
Affected individuals require lifelong care and are surviving longer than they have been in
the past; currently, survival into the fifth decade is common (Tarquinio et al., 2015).
Parents must balance their care between their affected child and their other children; a
commonly reported reason for reproductive stoppage included parents reporting wanting
to dedicate all their time to their current children. For example, one participant
responded, “After the diagnosis we choose to put all our efforts into giving our daughter
the best possible life that we could.” The second most common reason for reproductive
stoppage was due to fear or uncertainty of RTT happening again in a future child. Of
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note, some participants made the distinction that it was not solely another child with RTT
that was concerning but having another child with any kind of special needs, as the needs
of their affected child were so great. It is uncertain if recurrence of RTT or recurrence of
disability was more strongly associated with reproductive stoppage.
There is literature regarding reproductive stoppage in the presence of known
heritable genetic conditions, such a Fragile X syndrome. Mothers who are carries for
Fragile X syndrome have a 50% risk to have an affected son with each male pregnancy
and a 50% chance to have a carrier daughter with each female pregnancy. Raspberry &
Skinner et al. (2011) found fear of “social judgments” was a reason for reproductive
stoppage by Fragile X carrier mothers. While many parents of children with RTT
reported stopping due to the strain of having a child with a disability as well as fearing
having another child with similar needs, no participants reported feeling social pressure
or judgements when making family planning decisions. This could be due in part to the
fact that many parents are likely informing family and friends that RTT happened in their
child sporadically and there is a low chance for it to occur again; however, it is possible
there is pressure to stop having children to dedicate themselves to caring for their child
with special needs. Although stopping reproduction to dedicate more care to their
affected child was a commonly reported reason for stopping reproduction, no participants
reported that this was due to any kind of pressure from family, friends, or society.
In terms of reproductive continuation, many participants reported wanting a
sibling either for their child with RTT or for their typical child. A few reported wishing to
have another child that could help with the care of their child with RTT as he/she aged
and would require more care. Additionally, another set of participants wanted to have
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another typical child so that the lone sibling of an affected individual would not face the
burden of caring for him/her in adulthood alone. Adult siblings of individuals with
intellectual disabilities are known to take on a variety of roles when their sibling reaches
adulthood, including caregiver, friend, advocate, legal representative (such as a
guardian), and informal service coordinator (Hall & Rosetti, 2017). This could be a
possible motive behind parental desire for more typical children, but interpretations of
those future sibling roles were not explicitly stated by any respondents.
When families receive a diagnosis of RTT, frequently from a neurologist,
developmental pediatrician, or geneticist (Tarquinio et al., 2015), it is imperative they
receive genetic counseling. Genetic counseling is defined as the “process of helping
people understand and adapt to the medical, psychological and familial implications of
genetic contributions to disease” (National Society of Genetic Counselors’ Definition
Task Force, 2006). In the case of RTT, parents should receive counseling based on up-todate literature regarding the genetics of RTT, de novo vs. inherited RTT, recurrence risk
in future pregnancies, and potential genetic testing in the event of a suspected carrier
mother. Prior to this study, it was unclear to what extent parents of those with RTT were
receiving genetic counseling. Typically, genetic counseling is provided by a genetic
counselor. In areas where genetic counselors are not readily available, physicians or other
practitioners may provide this counseling. In the event a diagnosis is made by a
neurologist or developmental pediatrician, rather than a geneticist, there may be a delay
in reception of genetic counseling due to wait times for genetics referrals, or the family
may never receive genetic counseling at all. Less than half of respondents reported
receiving genetic counseling. Of those, the majority did receive counseling from a genetic
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counselor. It is possible, however, that participants received some degree of genetic
counseling but may not have been aware of it at the time due to the misunderstanding that
genetic counseling is only provided in a geneticist’s office, or only by a genetic
counselor. Even discussing recurrence risk with a physician qualifies as some degree of
genetic counseling. Therefore, reception of genetic counseling may be underreported in
this patient population.
Participants were invited to explain what they were told in general regarding
recurrence risk of RTT. Thematic analysis of these responses revealed that the majority
were told that there was a less than 1% chance, “minimal,” or “negligible” chance that
they would have another affected child. Of these responses, there were several
participants that reported specific information on recurrence risk in the presence of
gonadal mosaicism or carrier mothers. For example, one mother reported being told that
“although I, [the] mother, did not have any abnormalities in my genetic makeup, my eggs
may carry the genetic mutation.” Another participant discussed the changes to risk based
on carrier status: “If I (the mother) carry [the mutation] our chances go up. But if not it’s
like 1:100,000.” As stated previously, this information may have been shared by a genetic
counselor or another provider. Further investigation into information received by parents
from genetic counselors and information received from other practitioners is warranted.
However, no significant difference was reported regarding family planning decisions
between those that received genetic counseling and those that did not.
Other participants reported being told the chance for recurrence was “zero” or
impossible. It is unclear whether these participants were truly told the risk was zero, or if
that was their interpretation of a “1% of less” risk estimate. To some, zero and “1% or
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less” may be equivalent. Patients interpret risk estimates in a variety of ways, and it is not
clear whether the responses to this question were their own interpretation or were the
words of the genetic counselor or other provider. Many participants report not discussing
recurrence risk with a healthcare provider for a variety of reasons. Some chose not to
speak with a genetic counselor because they were not planning to have any more
children, while others reported simply not having this discussion at all. For others, the
chance of recurrence was simply not known at the time of their child’s diagnosis, and
they did not receive any information. A small subset of participants was told a risk
number greater than 1%, such as 5%, 25%, or 50%. One respondent who was found to be
an asymptomatic carrier of a MECP2 mutation reported that she was informed that there
was a 50% chance if the future baby was a boy and an unknown chance if the future baby
was a girl. It is possible that this participant was referring to the uncertainty of whether a
daughter would have highly skewed X-inactivation, but this is not clear based on her
response. In the presence of gonadal mosaicism, there can be a risk of up to 50% to have
another affected child; it is complicated to counsel on this number, however, since it is
virtually impossible to test eggs or sperm to determine the level of mosaicism. It is
unclear whether those that reported being informed of a 50% risk were told this in the
context of inheritance or of gonadal mosaicism.
Further, one of the four participants that reported being told a 50% recurrence risk
was found to be an asymptomatic carrier of a MECP2 mutation. This participant, a
mother of a male child with RTT, has a twin sister with RTT. In this case, she had a 50%
chance of passing on her X chromosome with the MECP2 mutation, and a 50% chance of
passing on her X chromosome without the MECP2 mutation, regardless of the sex of the
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baby. This mother had unique insight into family planning decisions when the mother is
an asymptomatic carrier. She reported
“…we got pregnant when [son with RTT] was around 1 year old. But we
terminated the pregnancy because we did not know what was wrong with him and
we did not know what to test for. We couldn't risk having another child with such
high needs. We got pregnant again and then the insurance company finally agreed
to let us do a full DNA test and found out that I am an asymptomatic carrier.
Praise the heavens that this second pregnancy did not have Rett syndrome.”
Her experience entails many different themes surrounding family planning, such as fear
and uncertainty of having another affected child, potential caregiver strain from having a
child with complex medical needs and pursuing parental genetic testing to determine
parental carrier status to gain a better understanding of their personal recurrence risk.
Limitations
This study had several limitations that were potential barriers to data analysis. Most of
the participants were educated Caucasian females. Having a more diverse pool of
participants may have given more insight into how different groups of people may
interpret recurrence risk, and how different groups deal with the strain of having a child
with a disability. Religion was not asked as a demographic question, but it is possible
religious and spiritual beliefs played a role in family planning.
This questionnaire was only distributed electronically. It is possible more groups
may have been reached with the use of a mailed paper survey, as many do not have
access to Internet, email, or social media sites where the questionnaire was distributed.
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Directions for Future Research
There has been little research in the field of genetic counseling regarding counseling
families on recurrence risk in the presence of a typically de novo condition, primarily
surrounding the possibility of gonadal mosaicism. Further, the RTT community may
benefit from analysis of current genetic counseling practices of genetic
counselors/geneticists, developmental pediatricians, and neurologists to assess their way
of reporting recurrence risk to parents. It is also unclear to what extent counseling on the
prognosis of RTT has to do with decisions regarding family planning. This could give
more insight into parent perceptions of the roles siblings of their children with RTT may
take on as children and as adults.
Conclusion
This present study was a pilot study into the perceptions of parents of children with RTT
of recurrence risk and how their family planning was impacted. It was found that more
participants altered their family planning based on non-genetic factors, such as caregiver
strain and desire for their children (both with RTT and without) to have siblings, rather
than their perception of the recurrence risk. Non-genetic factors were reported more
frequently by both groups of parents, those who stopped reproduction and those who
continued. Genetic counseling had no significant association with altering family
planning decisions. More research is needed to determine the extent families are
receiving genetic counseling and whether that includes the chance for the possibility of
gonadal mosaicism or asymptomatic carrier mothers.
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TABLES
Table 2.1 Demographics
Percentage Frequency
Relationship to Individual
with RTT

Race/Ethnicity

Education Level

Employment Status

Marital Status

Biological Mother
Biological Father
Total
Caucasian
African-American
Hispanic/Latino
Native American
Asian/Pacific Islander
Multiethnic
Prefer not to respond
Other
Total
Less than high school
High school diploma or
equivalent
Some college
Associate’s degree
Bachelor’s degree
Graduate degree
Prefer not to respond
Total
Employed
Unemployed
Stay-at-home parent
Student
Retired
Other
Total
Single
Married
Divorced/Separated
In a relationship but not
married
Total
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89.5
10.5
100
84.5
1.1
5.9
0.4
0.7
3
1.1
3.3
100
0.7
5.9

272
32
304
229
3
16
1
2
8
3
9
271
2
16

20.2
13.2
29
27.6
3.3
100
55
1.1
28.8
0.4
5.9
8.9
100
1.5
83.1
8.8
6.6

55
36
79
75
9
272
149
3
78
1
16
24
271
4
226
24
18

100

272

Table 2.2 Thematic Analysis of Family Planning Decisions Based on a Child’s Diagnosis
of RTT
Theme

Subthemes
Addition of another sibling
for their child with RTT
and/or for their typical
child

Affected Decision Making:
Decided to have more
children

Delayed having more
children/intentionally
altered children’s age gaps
from original plan
Interpreted recurrence risk
as low

Caregiver strain

Affected Decision Making:
Decided to cease having
children
Uncertainty or fear
regarding recurrence/Fear
of having another child
with RTT or other special
needs

Did Not Affect Decision
Making

Already pregnant when
diagnosis received
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Example(s)
“We wanted a sister for our
Rett daughter.”
“We wanted the typical
child to have a typical
sibling.”
“We delayed planning for a
third child to adjust to our
new life.”
“No, we were aware that
Rett is caused by a random
mutation and was unlikely
to repeat.”
“Rett syndrome consumes
your entire life, not just
severe complications with
your child. Your marriage,
relationships and you as
the caretaker, your health.”
“Not for fear of Rett but
because of the amount of
time and energy we would
have to devote to our
daughter.”
“I felt I couldn’t risk
bringing another child into
the world with Retts. I
couldn’t do that to another
child…”
“I could not take the risk of
another child potentially
having any type of special
needs.”
“We were nine months
pregnant with daughter #4
when we got the
diagnosis.”

“I was 47 when [child] was
diagnosed.”
Finished having
children/Had tubal ligation
or vasectomy prior to
diagnosis

“My husband chose to
have a vasectomy when
our child with RTT was a
newborn.”
“I was finished having
children when she got her
diagnosis.”

Planned to have more
children regardless of
diagnosis
Parental Disagreement

Unsure/Uncertain
Weighing Options

31

“We wanted a third child in
spite of our daughter’s
disability.”
“After my Rett daughter
passed in 2015, I have
considered another child.
My husband does not
agree.”
“I haven't fully decided
yet. I'd like to have another
but I’m worried about
coping and giving my
daughter with Rett
syndrome enough time and
input. I want her to achieve
All she can within the
sphere of her abilities. I
want to give my all to this.
At the same time I'd like
my older daughter to have
another sibling. I'm also
just scared.”

FIGURES
Unsure
6.60%

Yes
43%
No
50.40%

Figure 2.1 Parent Report: “Did your child's Rett syndrome diagnosis alter your family
planning?” (n=272)
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Fear of
recurrence
26%
Caregiver
Strain
54%
Desire to dedicate
care to affected
child
20%

Figure 2.2 Factors Involved in Ceasing to Have Children (n=70)
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Desire for sibling
32%
Different age gaps
between children
than originally
planned
46%
Interpreted
recurrence risk as
low
22%

Figure 2.3 Factors Involved in Having More Children (n=37)
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Other/Unspecified,
13%
Tubal
ligation/vasectomy
prior to diagnosis
10%

Finshed having
children
45%

No
change
20%
Already
pregnant
12%

Figure 2.4 Factors Involved in Deciding Not to Alter Family Planning (n=82)
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>1% Zero/Impossible
3.3%
chance
3.3%
Unknown
3.3%
Not
discussed
11.40%

1% or less
78.7%

Figure 2.5 Parental Understanding of Recurrence Risk (n=183)
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APPENDIX A
ONLINE QUESTIONNAIRE
Dear Parent,
My name is Erin Huggins and I am a graduate student in the Genetic Counseling Training
Program at the University of South Carolina. I am conducting a research study as part of
the requirements of my degree in Genetic Counseling, and I would like to invite you to
participate.
I am studying the impact a Rett syndrome diagnosis has on family planning. If you decide
to participate, you will be asked to complete an electronic survey. In particular, you will
be asked questions about your child’s diagnosis, decisions regarding genetic testing, and
your pregnancy history. Participation is voluntary, and you will be able to skip any
questions that you prefer not to answer. Those eligible to participate include biological
parents of an individual with a clinical and/or genetic diagnosis of Rett syndrome. If a
genetic diagnosis has been made, parents of individuals with a MECP2 alteration are
eligible. Those not eligible to participate includes parents of individuals with genetic
diagnosis of MECP2 duplication, FOXG1 alteration, or CDKL5 alteration.
Survey responses are anonymous. Surveys will only be accessible by myself and the
research team. So, please do not fill in your name, your child’s name, or other identifying
information on the survey. The results of the study may be published or presented at
professional meetings, but your identity will not be revealed. Taking part in this study is
your decision. Completion of all or part of the survey implies you have given your
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consent to participate. However, participation is not required, and you may exit the
survey at any time or decide not to answer any question with no penalty.
I will be happy to answer any questions you have about the study. You may contact me at
rettsyndromestudy@gmail.com if you have study related questions or problems. If you
have any questions about your rights as a research participant, you may contact the Office
of Research Compliance at the University of South Carolina at 803-777-7095.
Your time is greatly valued and appreciated. If you would like to participate, please
complete the following survey at your convenience. Thank you for your consideration.

Regards,
Erin Huggins
USC Genetic Counseling Student
rettsyndromestudy@gmail.com
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1. What is your relationship to the individual with Rett syndrome?
o Biological mother
o Biological father
o Other (please specify)

2. Has anyone else in your family been diagnosed with a neurodevelopmental disorder
(such as autism, ADD/ADHD, etc.)?
o Yes
o No
o Unsure

3. If yes, what is their relationship to you and their diagnosis?
Relationship:
Diagnosis:

4. How old was your child when she/he received a clinical diagnosis of Rett syndrome
(i.e., how old was your child when you were first told she/he had Rett syndrome)?
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5. Who diagnosed your child with Rett syndrome?
o Neurologist
o Geneticist
o Pediatrician
o Developmental Pediatrician
o Unsure
o Other (please specify)

6. Has your child had genetic testing (i.e., through a laboratory) to diagnose Rett
syndrome?
o Yes
o No
o Unsure

7. If yes, at what age did your child receive a genetic diagnosis (from a laboratory test)?

8. Who informed you of the genetic diagnosis?
o Neurologist
o Geneticist
o Pediatrician
o Developmental Pediatrician
o Unsure
o Other (please specify)
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9. Does your child have an alteration in the MECP2 gene?
o Yes
o No
o Unsure
o No, she/he has a change in a different gene (please specify)

10. During the pregnancy of your child who has Rett syndrome, was any prenatal genetic
screening or testing performed? Select all that apply.


First trimester screen (Blood test and ultrasound performed between 10 and 13
weeks gestation to screen for chromosomal conditions and some birth defects)



Second trimester/quad screen (Blood test performed between 15 and 22 weeks
gestation to screen for chromosomal conditions and major physical defects such
as spina bifida)



Non-Invasive Prenatal Screening (Blood test performed any time after 10 weeks
gestation to screen for chromosomal conditions, including those involving sex
chromosomes-not available prior to 2011)



Chorionic Villus Sampling (CVS) (Procedure in which a catheter is inserted
through the mother's cervix to take a small sample of cells from the placenta)



Amniocentesis (Procedure in which a needle is inserted through the mother's
abdomen to withdraw amniotic fluid from the sac surrounding the fetus)



Unsure



No
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11. What were the reasons for this screening/testing during pregnancy? Select all that
apply.


Routine screening



Advanced Maternal Age



Suspected genetic condition



Prefer not to respond



Not applicable



Other (please specify)

12. When your child was diagnosed with Rett syndrome, how many other children did
you already have?
o None
o Number of children

13. What ages were your other children at the time of your child’s diagnosis? Please list
each child's age separated by a comma (ex. 5,7).

14. Did you/the child's mother have any more pregnancies after your child was diagnosed
with Rett syndrome?
o Yes
o No
o Prefer not to respond
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15. Please indicate the number of pregnancies you/the child's mother had after your child
was diagnosed with Rett syndrome

16. You will be prompted to answer these questions for up to four subsequent
pregnancies. Only answer as many question sets as there were pregnancies after your
child was diagnosed with Rett syndrome.
Please answer the questions below for the first pregnancy after your child was diagnosed
with Rett syndrome.
o Was prenatal genetic screening for chromosome conditions, such as Down
syndrome, performed via a blood draw on this pregnancy (Note: this is not the
same as prenatal testing for Rett syndrome)?
o Yes
o No
o Unsure
o Prefer not to respond
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17. If yes, please select all that apply.


First trimester screen (Blood test and ultrasound performed between 10 and 13
weeks gestation to screen for chromosomal conditions and some birth defects)



Second trimester/quad screen (Blood test performed between 15 and 22 weeks
gestation to screen for chromosomal conditions and major physical defects such
as spina bifida)



Non-Invasive Prenatal Screening (Blood test performed any time after 10 weeks
gestation to screen for chromosomal conditions, including those involving sex
chromosomes-not available prior to 2011)



Other (please specify)

18. What were the reasons behind the decision to receive prenatal screening? Please
select all that apply.


Routine screening



Advanced Maternal Age



Suspected genetic condition



Other (please specify)
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19. Was prenatal diagnostic testing for chromosome conditions, such as Down syndrome,
performed for this pregnancy?
o Yes: Amniocentesis
o Yes: CVS
o No
o Unsure
o Prefer not to respond

20. If yes, what were the results of this test?

21. Was prenatal diagnostic testing for Rett syndrome performed on this pregnancy (via
amniocentesis or CVS)?
o Yes
o No

22. If yes, what were the results of this test?

23. What influenced the decision to receive (or not receive) prenatal diagnostic testing for
Rett syndrome? Your answer may be as detailed as you wish. You are not required to
answer this question.
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24. Did you/the child's mother have more than one pregnancy after your child was
diagnosed with Rett syndrome?
o Yes
o No

(Questions 16-24 repeat for up to 4 subsequent pregnancies)

51. Did your child's Rett syndrome diagnosis alter your family planning (i.e., the decision
to have more children)?
o Yes
o No
o Unsure

52. Please explain your response in as much detail as you wish.

53. Did either biological parent of your child with Rett syndrome receive genetic testing?
o Yes-biological mother received genetic testing
o Yes-biological father received genetic testing
o Yes-both parents received genetic testing
o No
o Unsure
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54. If yes, what were the results of the test?
Mother’s Genetic Test Results:
Father’s Genetic Test Results:

55. If yes, please describe what influenced the biological parent’s decision to have
genetic testing.
Mother’s Response:
Father’s Response:

56. Please explain to the best of your knowledge how Rett syndrome is inherited.

57. Were you told your chances of your future children being born with Rett syndrome?
o Yes
o No
o Unsure

59. Has your family ever received genetic counseling?
o Yes
o No
o Unsure
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60. If so, by whom?
o Certified genetic counselor
o Other physician or provider (please specify)

61. Have any of your child’s siblings had genetic testing?
o Yes
o No
o Unsure

62. If yes, please fill in the results for each individual tested in the following format:
gender/age/test result
Sibling 1:
Sibling 2:
Sibling 3:
Sibling 4:

63. What is your current age?

64. What was your age at the time your child with Rett syndrome was born?

65. How old is your child with Rett syndrome currently?
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66. Is your child with Rett syndrome female or male?
o Female
o Male

67. What is your race/ethnicity? Check all that apply.


Caucasian



African-American



Hispanic or Latino



Native American or American Indian



Asian/Pacific Islander



Prefer not to respond



Other (please specify)

68. What is your highest degree of education?


Less than high school



High school diploma or equivalent



Some college



Associate’s degree



Bachelor’s degree



Graduate degree



Prefer not to respond
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69. What is your employment status?
o Employed
o Unemployed
o Stay-at-home parent
o Student
o Retired
o Prefer not to respond
o Other (please specify)

70. What is your marital status?
o Single
o Married
o Divorced/Separated
o In a relationship but not married
o Prefer not to respond
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